These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26748833)

  • 1. Effectiveness of bevacizumab exposure beyond disease progression in patients with non-small-cell lung cancer: analyses of the ARIES observational cohort study.
    Leon L; Kosty M; Jahanzeb M; Spigel D; Wozniak AJ; Brahmer J; Fish S; Flick ED; Hazard SJ; Lynch TJ
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):569-77. PubMed ID: 26748833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.
    Kosty MP; Wozniak AJ; Jahanzeb M; Leon L; Fish S; Hazard SJ; Lynch TJ
    Target Oncol; 2015 Dec; 10(4):509-16. PubMed ID: 25559289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
    Grothey A; Flick ED; Cohn AL; Bekaii-Saab TS; Bendell JC; Kozloff M; Roach N; Mun Y; Fish S; Hurwitz HI
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):726-34. PubMed ID: 24830357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.
    Wozniak AJ; Kosty MP; Jahanzeb M; Brahmer JR; Spigel DR; Leon L; Fish S; Flick ED; Hazard SJ; Lynch TJ
    Clin Oncol (R Coll Radiol); 2015 Apr; 27(4):187-96. PubMed ID: 25576353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.
    Lynch TJ; Spigel DR; Brahmer J; Fischbach N; Garst J; Jahanzeb M; Kumar P; Vidaver RM; Wozniak AJ; Fish S; Flick ED; Leon L; Hazard SJ; Kosty MP;
    J Thorac Oncol; 2014 Sep; 9(9):1332-9. PubMed ID: 25122429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
    Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
    Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Nishijima-Futami Y; Minami S; Futami S; Koba T; Higashiguchi M; Tamiya M; Suzuki H; Hirashima T; Komuta K; Kijima T
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
    Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
    Takeda M; Yamanaka T; Seto T; Hayashi H; Azuma K; Okada M; Sugawara S; Daga H; Hirashima T; Yonesaka K; Urata Y; Murakami H; Saito H; Kubo A; Sawa T; Miyahara E; Nogami N; Nakagawa K; Nakanishi Y; Okamoto I
    Cancer; 2016 Apr; 122(7):1050-9. PubMed ID: 26828788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
    Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
    Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
    J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
    Matikas A; Kentepozidis Ν; Ardavanis A; Vaslamatzis M; Polyzos A; Emmanouilides Ch; Katsaounis P; Koinis F; Xynogalos S; Christopoulou A; Ziras N; Tegos T; Prinarakis E; Hatzidaki D; Georgoulias V; Kotsakis A;
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):369-76. PubMed ID: 27335027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study].
    Chouaid C; Falchero L; Schott R; Bonnetain F; Taguieva-Pioger N; Bennouna J
    Rev Mal Respir; 2017 Jan; 34(1):36-43. PubMed ID: 27266900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer.
    Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
    Thorac Cancer; 2018 Dec; 9(12):1716-1724. PubMed ID: 30324773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
    Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
    Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.